TransMedics price target raised to $147 from $142 at Canaccord

Canaccord raised the firm’s price target on TransMedics (TMDX) to $147 from $142 and keeps a Buy rating on the shares. The firm said they delivered revenue in line with the firm’s estimates, but slightly short of consensus which may present an interesting buying opportunity. Given the expectation for a seasonally slow and relatively in-line quarter, they believe their thesis is intact and believe any dip in the stock price creates a buying opportunity for longer-term investors,